CA3173702A1 - Novel spiropyrrolidine derived antiviral agents - Google Patents

Novel spiropyrrolidine derived antiviral agents Download PDF

Info

Publication number
CA3173702A1
CA3173702A1 CA3173702A CA3173702A CA3173702A1 CA 3173702 A1 CA3173702 A1 CA 3173702A1 CA 3173702 A CA3173702 A CA 3173702A CA 3173702 A CA3173702 A CA 3173702A CA 3173702 A1 CA3173702 A1 CA 3173702A1
Authority
CA
Canada
Prior art keywords
optionally substituted
compound
nri3r14
acetone
nmr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3173702A
Other languages
English (en)
French (fr)
Inventor
Ruichao Shen
Yong He
Xuechao Xing
Matthew C. Rhodes
Joseph D. Panarese
Samuel Bartlett
Wei Li
Hui Cao
Jiajun Zhang
Xiaowen Peng
Guoqiang Wang
Yat Sun Or
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Enanta Pharmaceuticals Inc
Original Assignee
Enanta Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US17/479,248 external-priority patent/US11325916B1/en
Application filed by Enanta Pharmaceuticals Inc filed Critical Enanta Pharmaceuticals Inc
Publication of CA3173702A1 publication Critical patent/CA3173702A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3173702A 2021-07-29 2022-04-14 Novel spiropyrrolidine derived antiviral agents Pending CA3173702A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163227206P 2021-07-29 2021-07-29
US63/227,206 2021-07-29
US17/479,248 2021-09-20
US17/479,248 US11325916B1 (en) 2021-07-29 2021-09-20 Spiropyrrolidine derived antiviral agents
US202263324367P 2022-03-28 2022-03-28
US63/324,367 2022-03-28
PCT/US2022/024772 WO2023009187A1 (en) 2021-07-29 2022-04-14 Novel spiropyrrolidine derived antiviral agents

Publications (1)

Publication Number Publication Date
CA3173702A1 true CA3173702A1 (en) 2023-01-29

Family

ID=85087186

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3173702A Pending CA3173702A1 (en) 2021-07-29 2022-04-14 Novel spiropyrrolidine derived antiviral agents

Country Status (8)

Country Link
EP (1) EP4376834A4 (cg-RX-API-DMAC10.html)
JP (1) JP2024529476A (cg-RX-API-DMAC10.html)
KR (1) KR20240044452A (cg-RX-API-DMAC10.html)
AU (1) AU2022319598A1 (cg-RX-API-DMAC10.html)
CA (1) CA3173702A1 (cg-RX-API-DMAC10.html)
IL (1) IL310246A (cg-RX-API-DMAC10.html)
MX (1) MX2024001377A (cg-RX-API-DMAC10.html)
WO (1) WO2023009187A1 (cg-RX-API-DMAC10.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7559223B2 (ja) 2020-08-24 2024-10-01 ギリアード サイエンシーズ， インコーポレイテッド リン脂質化合物及びその使用
TWI925033B (zh) 2020-10-16 2026-05-11 美商基利科學股份有限公司 磷脂化合物及其用途
WO2023283256A1 (en) 2021-07-09 2023-01-12 Aligos Therapeutics, Inc. Anti-viral compounds
AU2023303408A1 (en) 2022-07-06 2024-12-19 Aligos Therapeutics, Inc. Anti-viral compounds
EP4612156A1 (en) * 2022-11-02 2025-09-10 Aligos Therapeutics, Inc. Anti-viral compounds
CN119139307B (zh) * 2023-12-29 2025-09-23 上海柯君医药科技有限公司 螺环类化合物在制备3CLpro蛋白酶抑制剂或药物中的用途
WO2025221657A1 (en) * 2024-04-15 2025-10-23 Aligos Therapeutics, Inc. Anti-viral compounds

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006061714A2 (en) * 2004-12-09 2006-06-15 Pfizer Inc. Anticoronaviral compounds and compositions, their pharmaceutical uses and materials for their synthesis
US8222288B2 (en) * 2006-08-30 2012-07-17 The Regents Of The University Of Michigan Small molecule inhibitors of MDM2 and the uses thereof
CA2661354C (en) * 2006-08-30 2012-12-18 The Regents Of The University Of Michigan New small molecule inhibitors of mdm2 and the uses thereof
US8575208B2 (en) * 2007-02-27 2013-11-05 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
UY37381A (es) * 2016-08-30 2018-03-23 Glaxosmithkline Ip No 2 Ltd Compuestos que inhiben proteasas 3c y 3cl y métodos de uso de los mismos
US12398147B2 (en) * 2021-05-11 2025-08-26 Enanta Pharmaceuticals, Inc. Macrocyclic spiropyrrolidine derived antiviral agents
US11325916B1 (en) * 2021-07-29 2022-05-10 Enanta Pharmaceuticals, Inc. Spiropyrrolidine derived antiviral agents
WO2023086400A1 (en) * 2021-11-12 2023-05-19 Enanta Pharmaceuticals, Inc. Novel spiropyrrolidine derived antiviral agents
WO2023125825A1 (en) * 2021-12-29 2023-07-06 Shanghai Curegene Pharmaceutical Co., Ltd. Anticoronviral compounds and compositions and uses thereof

Also Published As

Publication number Publication date
KR20240044452A (ko) 2024-04-04
EP4376834A4 (en) 2025-06-18
WO2023009187A1 (en) 2023-02-02
AU2022319598A1 (en) 2024-02-08
EP4376834A1 (en) 2024-06-05
IL310246A (en) 2024-03-01
JP2024529476A (ja) 2024-08-06
MX2024001377A (es) 2024-03-08

Similar Documents

Publication Publication Date Title
AU2021381437B2 (en) Novel spiropyrrolidine derived antiviral agents
ES2936277B2 (es) Peptidos funcionalizados como agentes antivirales
US12479854B2 (en) Spiropyrrolidine derived antiviral agents
US12540141B2 (en) Spiropyrrolidine derived antiviral agents
CA3189248A1 (en) Functionalized peptides as antiviral agents
CA3202764A1 (en) Novel spiropyrrolidine derived antiviral agents
WO2019094920A1 (en) Azepin-2-one derivatives as rsv inhibitors
WO2018226801A1 (en) Aryldiazepine derivatives as rsv inhibitors
WO2023107419A1 (en) Saturated spirocyclics as antiviral agents
WO2023091561A1 (en) Novel spiropyrrolidine derived antiviral agents
WO2023086350A1 (en) Alkyne-containing antiviral agents
WO2023086400A1 (en) Novel spiropyrrolidine derived antiviral agents
WO2023196307A1 (en) Novel spiropyrrolidine derived antiviral agents
IL310246A (en) Novel spiropyrrolidine derived antiviral agents
US12145941B2 (en) Heterocyclic antiviral agents
AU2007272839A1 (en) 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication
EA050743B1 (ru) Новые противовирусные агенты на основе производных спиропирролидина
HK40071048A (en) Novel spiropyrrolidine derived antiviral agents

Legal Events

Date Code Title Description
D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D120 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: VOLUNTARY SUBMISSION OF PRIOR ART RECEIVED

Effective date: 20241001

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241220

R00 Party data change recorded

Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R00-R113 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF ADDRESS OR METHOD OF CORRESPONDENCE REQUEST RECEIVED

Effective date: 20250120

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D123 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIOR ART DISCLOSURE DETERMINED COMPLIANT

Effective date: 20250318

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250318

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250407

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250407

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260323

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260323

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260408

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260408

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R18-R143 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF ADDRESS REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260422

Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R18-R114 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF METHOD OF CORRESPONDENCE REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260422

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260422